Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Michael R. McMullen, a director at Bristol-Myers Squibb, acquired deferred share units convertible to common stock on September 30, 2024.

Summary

• On September 30, 2024, Michael R. McMullen, a director of Bristol-Myers Squibb, acquired 603.981 deferred share units.
• These units are convertible into shares of common stock upon settlement, which occurs when McMullen ceases to be a director or at a previously specified future date.
• The price of the derivative security was $51.74.
• Following the transaction, McMullen beneficially owns 3,628.127 derivative securities, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of a routine transaction. It doesn't indicate positive or negative sentiment about the company's prospects.

Future Outlook

The deferred share units will be converted into common stock upon settlement when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Form 4 filings are routine disclosures of transactions by company insiders, providing transparency into their investment activities and sentiment regarding the company's stock.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects an insider's continued investment in the company.

Key Dates